A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle

American Journal of Physiology - Endocrinology and Metabolism

Volumn 280, Issue 2 43-2, 2001, Pages

  Minnich, Anne ^a,b   Tian, Nian ^a   Byan, Lisa ^a   Bilder, Glenda ^a  

^a Aventis Pharmaceuticals   (United States)

^b SANOFI   (France)

Author keywords

Carnitine palmitoyltransferase I; Fibrates; Gene expression; Nuclear receptors; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN C; CARNITINE PALMITOYLTRANSFERASE; FENOFIBRIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; UNCLASSIFIED DRUG; UREIDO FIBRATE 5; CARBANILAMIDE DERIVATIVE; CELL RECEPTOR; DRUG DERIVATIVE; FATTY ACID; FENOFIBRATE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; FATTY ACID OXIDATION; GENE EXPRESSION; HAMSTER; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; LIPID METABOLISM; LIVER MITOCHONDRION; METABOLISM; MUSCLE MITOCHONDRION; OXIDATION REDUCTION REACTION; SYRIAN HAMSTER; TIME;

ANIMALS; CRICETINAE; DIETARY FATS; FATTY ACIDS; LIPID METABOLISM; MALE; MESOCRICETUS; MITOCHONDRIA, LIVER; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PHENYLUREA COMPOUNDS; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0035024343     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2001.280.2.e270     Document Type: Article

References (35)

1. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, and Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased Apo CIII and reduced Apo E on the particles. J Clin Invest 90: 1889-1900, 1992.
2. Brandt JM, Djouadi F, and Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273: 23786-23792, 1998.
3. Britton CH, Schultz RA, Zhang B, Esser V, Foster DW, and Mcgarry JD. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci USA 92: 1984-1988, 1995.
4. Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, and Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity. J Med Chem 42: 3785-3788, 1999.
5. Chatelain F, Kohl C, Esser V, Mcgarry JD, Girard J, and Pegorier JP. Cyclic AMP and fatty acids increase carnitine palmitoyltransferase I gene transcription in cultured fetal rat hepatocytes. Eur J Biochem 235: 789-798, 1996.
6. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, and Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998.
7. Esser V, Britton CH, Weis BC, Foster DW, and Mcgarry JD. Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase I. Direct evidence that a single polypeptide is involved in inhibitor interaction and catalytic function. J Biol Chem 268: 5817-5822, 1993.
8. Frohnert BI, Hui TY, and Bernlohr DA. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 274: 3970-3977, 1999.
9. Froyland L, Madsen L, Vaagenes H, Totland GK, Auwerx J, Kryvi H, Staels B, and Berge RK. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 38: 1851-1858, 1997.
10. Gulick T, Cresci S, Caira T, Moore DD, and Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91: 11012-11016, 1994.
11. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, and Goldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 100: 475-482, 1999.
12. Hawke RL, Chapman JM, Winegar DA, Salisbury JA, Welch RM, Brown A, Franzmann KW, and Sigel C. Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity. J Lipid Res 38: 1189-1203, 1997.
13. Hokanson JE and Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3: 213-219, 1996.
14. Holden PR and Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 22: 1-8, 1999.
15. Issemann I and Green S. Activation of a member of the steroid hormone superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
16. Krause BR and Princen HMG. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 140: 15-24, 1998.
17. Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, and Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022, 1995.
18. Martin G, Schoonjans K, Lefebvre AM, Staels B, and Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR alpha and PPAR gamma activators. J Biol Chem 272: 28210-28217, 1997.
19. Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, and Haro D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 273: 8560-8563, 1998.
20. Moon A and Rhead WJ. Complementation analysis of fatty acid oxidation disorders. J Clin Invest 79: 59-64, 1987.
21. Mukherjee R, Jow L, Noonan D, and McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51: 157-166, 1994.
22. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, and Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272: 27307-27312, 1997.
23. Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi T, Hashimoto T, and Lalwani ND. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci USA 83: 1747-1751, 1986.
24. Rodriguez JC, Gil-Gomez G, Hegardt FG, and Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem 269: 18767-18772, 1994.
25. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, and Auwerx J. Induction of the acyl-coenzyme A synthetase gene by flbrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270: 19269-19276, 1995.
26. Sehayek E and Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266: 18259-18267, 1991.
27. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JG. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998.
28. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, and Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712, 1995.
29. Sullivan MP, Cerda JJ, Robbins FL, Burgin CW, and Beatty RJ. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci 43: 575-578, 1993.
30. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, and Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96: 741-750, 1995.
31. Williams GM and Perrone C. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Ann NY Acad Sci 804: 554-572, 1996.
32. Windler E, Chao Y, and Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 255: 8303-8307, 1980.
33. Yamazaki N, Shinohara Y, Shima A, and Terada H. High expression of a novel carnitine palmitoyltransferase I like protein in rat brown adipose tissue and heart: isolation and characterization of its cDNA clone. FEBS Lett 363: 41-45, 1995.
34. Yamazaki N, Shinohara Y, Shima A, Yamanaka Y, and Terada H. Isolation and characterization of cDNA and genomic clones encoding human muscle type carnitine palmitoyltransferase I. Biochim Biophys Acta 1307: 157-161, 1996.
35. Yu GS, Lu YC, and Gulick T. Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase I beta gene promoters by fatty acid enzyme substrate. J Biol Chem 273: 32901-32909, 1998.